Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merit Medical Systems, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Begins integrating Mallinckrodt catheter unit following completion of the acquisition, announced Aug. 25 (1"The Gray Sheet" July 26, p. 24)

You may also be interested in...



Merit/Mallinckrodt

Merit Medical Systems will acquire Mallinckrodt's $10 mil.-per-year diagnostic and interventional catheter production facility in Angleton, Texas for undisclosed terms under a July 21 agreement in principle. The purchase "strengthens our sales and new product development objectives by adding...revenue as well as providing a depth of core technology for future catheter development," Merit Chairman and CEO Fred Lampropoulos explains. Strategically, the non-core Mallinckrodt business complements Merit's current offerings and will allow consolidation of some existing catheter products into the Angleton facility for greater plant utilization. The deal is expected to close in August subject to a binding agreement. Separately, Merit announces a 28% increase in second-quarter net income to $752,684 on revenues of $19 mil., up 5.6%

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel